A prognostic index for progression-free survival in malignant mesothelioma with application to the design of phase II trials: a combined analysis of 10 EORTC trials.
about
Biomarkers and prognostic factors for mesotheliomaGuidelines for the diagnosis and treatment of malignant pleural mesotheliomaSupplementary prognostic variables for pleural mesothelioma: a report from the IASLC staging committee.Determinants of long-term outcome in patients undergoing simultaneous resection of synchronous colorectal liver metastasesRe-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1).SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM)Post-chemotherapy T-cell recovery is a marker of improved survival in patients with advanced thoracic malignancies.Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107).Disease volumes as a marker for patient response in malignant pleural mesothelioma.A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307.Translational advances in pleural malignancies.Malignant pleural mesothelioma: when is radiation therapy indicated?Biomarkers and prognostic factors for malignant pleural mesothelioma.Prognostic significance of neutrophil-to-lymphocyte ratio in patients with malignant pleural mesothelioma: a meta-analysisClinical staging of malignant pleural mesothelioma: current perspectives.A new prognostic index for overall survival in malignant pleural mesothelioma: the rPHS (regimen, PS, histology or stage) index.
P2860
Q28387194-640A4901-57F4-4C8D-B643-3ABA941D9E39Q28394028-4E7B8A50-4420-476E-96E7-F742D2E13D90Q34041728-AC458F9C-533C-43D7-B890-276795781EC4Q34097450-DD94BB00-DE19-4417-AF28-C03BB93B270BQ34520155-0E26414C-3635-4A4A-AD90-975E7C49D0BBQ35006450-D246DE44-2893-48C9-9CFA-1B68A23B8782Q36287976-4BE1AB1E-7564-47E7-91D3-8E66D616BFBEQ36652941-7C83E2E5-3E3D-4095-9970-4F1C13DC0E86Q36702389-57BDE3E8-609A-4C29-81E7-44DA014E4955Q37296603-1BA805B6-BFD5-4626-B723-6ACF1229C395Q37806309-87E9A399-A7C2-4C3F-8A8C-9BD4A2DFB9EFQ37866786-DC7B3691-F970-475C-918D-E1F0ECAAEA32Q38660038-F5A69DD5-440C-46DE-8F4E-44979B159DD8Q41341293-6B7CF273-7D8F-4FE8-B6EE-1288C504C16BQ41522440-1764210A-AC9C-48DD-9583-D3406333453AQ51643878-7F04530C-6CB2-4DA2-BEA7-3FB6785DEF5E
P2860
A prognostic index for progression-free survival in malignant mesothelioma with application to the design of phase II trials: a combined analysis of 10 EORTC trials.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
A prognostic index for progres ...... d analysis of 10 EORTC trials.
@en
A prognostic index for progres ...... d analysis of 10 EORTC trials.
@nl
type
label
A prognostic index for progres ...... d analysis of 10 EORTC trials.
@en
A prognostic index for progres ...... d analysis of 10 EORTC trials.
@nl
prefLabel
A prognostic index for progres ...... d analysis of 10 EORTC trials.
@en
A prognostic index for progres ...... d analysis of 10 EORTC trials.
@nl
P2093
P1476
A prognostic index for progres ...... d analysis of 10 EORTC trials.
@en
P2093
J Francart
J P van Meerbeeck
R Sylvester
P304
P356
10.1016/J.EJCA.2009.04.028
P577
2009-06-06T00:00:00Z